FDA OKs Cognition as Sole Outcome Measure for Preclinical AD Trials
The agency is accepting comments on a draft guidance that updates its recommendations for early AD trials, as well as on its first-ever guidance for ALS drug development.
6471 RESULTS
Sort By:
The agency is accepting comments on a draft guidance that updates its recommendations for early AD trials, as well as on its first-ever guidance for ALS drug development.
People with inflammatory bowel disease are at higher risk for Parkinson’s—but not if they take anti-inflammatory medication.
Contrary to previous findings, both proteins seem to escape via passive diffusion. This has implications for therapeutic strategies to keep them where they belong.
By prying open chromatin, neurofibrillary tau may expose dormant transposable elements for transcription.
Microfluidic tri-culture of neurons, astrocytes, and microglia models how glia impose deadly neuroinflammation on top of amyloid and tau pathology.
The 2019 budget ups this year’s spending by $425 million.
A molecular-level view of tau filaments from a person with Pick’s disease reveals that the protein folds up differently than it does in Alzheimer’s disease.
A behavioral intervention slowed memory slippage and functional decline over two years.
In DIAN, participants who are more physically active may also have slower disease progression.
A small molecule that protects neurons fends off a short region of Aβ from a specific pocket on the LilrB2 receptor.
Analysis of MRI brain volume data identifies multiple AD and FTD/ALS disease subtypes with distinct patterns of degeneration over time.
Clusters of neurons harboring somatic mutations in 56 genes linked to neurodegenerative diseases may be commonplace in the human brain.
In several model systems, α-synuclein boosts oleic acid production and the fatty acid worsens α-synuclein pathology.
In presynapses, binding sequesters synaptic vesicles.
A leaky blood-brain barrier in the hippocampus correlated with cognitive impairment, independently of other vascular risk factors or Alzheimer’s pathology.